ID
27536
Description
Study Part: Study Conclusion Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165
Keywords
Versions (1)
- 11/19/17 11/19/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
November 19, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Study Conclusion Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165
Study Conclusion Follow- Up (Visit 10)
- StudyEvent: ODM
Similar models
Study Conclusion Follow- Up (Visit 10)
- StudyEvent: ODM
C0008972 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
C2349954 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,3])
C0008976 (UMLS CUI [1,4])
C0011008 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
No comments